Please Remember When You Could Get A New CX-5461 For Free, But You Did Not?

To confirm these results, we then evaluated prospectively bone metabolism of 99 patients http://www.selleckchem.com/products/forskolin.html who received either RD or VRD (bortezomib, lenalidomide, and dexamethasone) in the context of a clinical study [24]. Patients with relapsed or refractory myeloma after one or more prior therapies were treated with RD, regardless of their performance status, renal function, prior peripheral neuropathy, and prior treatment with high-dose dexamethasone, thalidomide, or bortezomib. Patients who were previously treated with lenalidomide were not included. Refractory disease was termed as progression during prior treatment or within 60 days of discontinuation of prior treatment while relapsed disease was termed as progression at least 60 days after completion of prior treatment. All patients received prophylaxis for deep vein http://www.selleck.cn/products/AZD0530.html thrombosis (DVT) with aspirin 100 mg/day unless they were already on coumadin or on low molecular weight heparin (LMWH) for pre-existing DVT or for other indications, usually atrial fibrillation. Response assessment was based on the International Myeloma Working Group (IMWG) criteria [25]. The National Cancer Institute's Common Toxicity Criteria (version 3) were used to grade adverse effects for toxicity being related to treatment. Informed consent was obtained from all patients. Lenalidomide was administered at a dose of 25 mg PO daily on Days 1�C21 of a 28-day cycle if the baseline creatinine clearance (CrCl) was >50 m/min. For patients with http://www.selleckchem.com/products/cx-5461.html lower CrCl the following adjustments were made: lenalidomide 10 mg/day for patients with CrCl ��30 ml/min, 15 mg every other day for patients with CrCl